Displaying drugs 6801 - 6825 of 8037 in total
MBX-2109
MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.
Investigational
Matched Description: … MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of …
Rovaleucel
Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.
Investigational
Matched Description: … Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive …
Ciglitazone
Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.
Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market....
Experimental
Matched Description: … Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. ... Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones ... Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to …
MYR-101
MYR-101 (rAAV-Olig001-ASPA) is a recombinant adeno-associated virus (rAAV) vector-based gene therapy intended to treat Canavan disease. Canavan disease is a fatal childhood genetic disorder characterized by white matter degeneration in the brain. It is caused by a mutation in the aspartoacylase gene (ASPA), which leads to a deficiency of the...
Investigational
Matched Description: … ASPA is produced in oligodendrocytes, and participates in the metabolism of N-acetylaspartate (NAA). ... granted MYR-101 Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for the treatment of ... It is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase …
D-1,4-dithiothreitol
A reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]
Experimental
Matched Description: … A reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH ( …
Sphingosine
An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed)
Experimental
Matched Description: … Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. …
N-acetyl-alpha-neuraminic acid
An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518)
Experimental
Matched Description: … An N-acyl derivative of neuraminic acid. …
N-acetyl-beta-neuraminic acid
An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518)
Experimental
Matched Description: … An N-acyl derivative of neuraminic acid. …
Bafetinib
Bafetinib has been used in trials studying the treatment of Adult Gliosarcoma, Adult Mixed Glioma, Adult Glioblastoma, Chronic Myeloid Leukemia, and Acute Lymphocytic Leukemia, among others.
Investigational
Matched Description: … Bafetinib has been used in trials studying the treatment of Adult Gliosarcoma, Adult Mixed Glioma, Adult …
Savolitinib
Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.
Investigational
Matched Description: … Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food …
Denenicokin
Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma).
Investigational
Matched Description: … Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL …
Lobaplatin
Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, and Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma.
Investigational
Matched Description: … Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, …
Poly(lactic acid)
Poly(lactic acid) is under investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy).
Investigational
Matched Description: … investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of …
Istiratumab
Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
Investigational
Matched Description: … Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel …
Cerdulatinib
Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)).
Investigational
Matched Description: … Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib …
NCX-1000
NCX-1000 is under investigation in clinical trial NCT00414869 (Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure).
Investigational
Matched Description: … NCX-1000 is under investigation in clinical trial NCT00414869 (Preliminary Efficacy and Tolerability of …
Indatuximab ravtansine
Indatuximab ravtansine is under investigation in clinical trial NCT01001442 (Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma).
Investigational
Matched Description: … is under investigation in clinical trial NCT01001442 (Safety and Dose Determining Multi-dose Study of …
Pegylated Recombinant Human Arginase I
Pegylated Recombinant Human Arginase I is under investigation in clinical trial NCT03455140 (A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)).
Investigational
Matched Description: … I is under investigation in clinical trial NCT03455140 (A Study Evaluating the Safety and Activity of …
Quavonlimab
Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).
Investigational
Matched Description: … Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination …
SAR421869
SAR421869 is a Lentiviral Vector Containing The Human My07A Gene currently being investigated for the treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.
Investigational
Matched Description: … a Lentiviral Vector Containing The Human My07A Gene currently being investigated for the treatment of …
CZEN 002
CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). CZEN-002 modulates inflammatory and immune responses. It has also been shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of infections, including vaginitis. This organism can invade tissues and produce fatal...
Investigational
Matched Description: … Studies attempting to understand the candidacidal activity of derivatives of alpha-MSH have focused on ... shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of ... The antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial …
ADL5859
ADL5859 is a novel, oral compound that targets the Delta opioid receptor. Delta receptor agonists are thought to offer benefits over other approaches to the management of pain.
Investigational
Matched Description: … Delta receptor agonists are thought to offer benefits over other approaches to the management of pain …
Vatreptacog alfa
Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors.
Investigational
Matched Description: … Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia …
Evogliptin
Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.
Investigational
Matched Description: … Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment …
5-fluoro-2'-deoxycytidine
5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, and Urinary Bladder Neoplasms, among others.
Investigational
Matched Description: … 5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms …
Displaying drugs 6801 - 6825 of 8037 in total